ABSTRACT
Background Hemoglobin (Hb) elevation is the hallmark of high-altitude adaptation, yet its effect on surgical outcomes may depend on arterial oxygen saturation (SpO2)--previously uninvestigated.
Objectives To explore whether preoperative Hb effect on postoperative length of stay (LOS) after laparoscopic cholecystectomy (LC) reverses across SpO2 strata.
Methods Retrospective single-center cohort of 612 adults undergoing elective LC (2018-2023) at Qinghai Red Cross Hospital, Xining, China (2260 m). Exposure: preoperative Hb (82-233 g/L) and SpO2 (86%-99%), stratified as low (<93%), mid (93%-95%), high (>=96%). Primary analysis: multivariable linear regression with Hb x SpO2 interaction, adjusted for BMI, age, sex, season.
Results Among 612 patients (65.8% female; mean age 43.5 [11.9] years; mean Hb 151.4 [20.7] g/L; mean SpO2 94.6% [2.3%]), the Hb x SpO2 interaction was significant (beta = −0.0095; P = .009). Hb effect reversed: in SpO2 >=93%, each 1 g/L Hb prolonged LOS by 0.003 days (P = .079); in SpO2 <93%, each 1 g/L reduced LOS by 0.006 days. In mid-SpO2 stratum (n = 251), Hb >=180 g/L had longer LOS (1.88 vs 1.62 days; P = .001; d = 0.54). Five computational robustness analyses confirmed the interaction (leave-one-out: 100% P < .05 across 612 iterations).
Conclusions In this exploratory cohort, we observed an SpO2-dependent reversal of the Hb effect on postoperative LOS, designated the “Plateau Hemoglobin Paradox.” Given single-center design and power of 0.754, findings require replication. If replicated, this pattern may inform future perioperative risk stratification at high altitude.
Competing Interest Statement
The authors have declared no competing interest.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Committee of Qinghai Red Cross Hospital gave ethical approval for this work (Approval No. LW-2026-73)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Funder Information Declared
